MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference

MARIETTA, Ga. /PRNewswire/ --MiMedx (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts reporting on the Company's EpiFix® dehydrated Human Amnion/Chorion Membrane (dHACM) allograft and EpiCord® dehydrated human umbilical cord (dHUC) allograft will be presented at the Desert Foot 15th Annual Multi-Disciplinary Limb Salvage Conference in Phoenix, Arizona. The conference begins Wednesday, November 7, 2018, and concludes on Saturday, November 10, 2018. 

MiMedx will sponsor a symposium entitled, "Clinical Efficacy of EpiFix and AmnioFix dehydrated human amnion/chorion membrane allografts in Surgical and Wound Care Applications" on Wednesday, November 7^th in the Phoenix Ballroom main lecture hall. The symposium faculty and presenters include Ray Ortega, MD, MiMedx Medical Director, and Jeremy Lim, PhD, Senior R&D Engineer at MiMedx.

Dr. Ortega, a former Army Special Forces Officer (Green Beret) and Medical Corps plastic surgeon, will review two recent EpiFix and EpiCord multicenter DFU randomized control trial (RCTs) studies.  The first is entitled: "A Confirmatory Study on the Efficacy of Dehydrated Human Amnion/Chorion Membrane (EpiFix®) Allograft in the Management of Diabetic Foot Ulcers: A Prospective, Multicenter, Randomized, Controlled Study of 110 Patients from 14 Wound Clinics." The second is: "A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers."

Dr. Lim will provide an overview of the MiMedx research study published in the Journal of Biomedical Materials Research that evaluated dHUC and its biological properties. It was the first published characterization of dHUC tissue.

During a sponsored hands-on workshop on November 8, David Kyle, DPM, will present "Application Techniques and Therapeutic Approaches Using EpiFix, EpiCord & AmnioFix Allografts for Wound Healing and Surgical Procedures". MiMedx will also sponsor a workshop during the Amputation/ Limb Salvage Continuum of Care Skills course on November 10.

The five poster abstracts will report on MiMedx EpiFix and EpiCord allografts, as follows:

1. William Tettelbach, MD; Shawn Cazzell, DPM; Alexander M. Reyzelman, DPM; Felix Sigal, DPM; Joseph M. Caporusso, DPM; Patrick S. Agnew, DPM: A Prospective, Multicenter, Randomized, Controlled Study Confirming the Efficacy of Dehydrated Human Amnion/Chorion Membrane Allograft in the Management of Diabetic Foot Ulcers
2. William Tettelbach, MD; Shawn Cazzell, DPM; Felix Sigal, DPM; Joseph M. Caporusso, DPM; Patrick S. Agnew, DPM; Jason Hanft, DPM; Cyaandi Dove, DPM: A Multicenter Prospective Randomized Controlled Comparative Parallel Study of Dehydrated Human Umbilical Cord Allograft for the Treatment of Diabetic Foot Ulcers  
3. Brandon Brooks, DPM PGY-3; Kevin Pham, DPM PGY-4; Bradley Brooks, DO PGY-2; Brady Brooks, MSII; James Henry, MSII; Charles Kean, DPM; Terria Madison, DPM: Intraoperative Use of Umbilical Cord Allograft in Achilles Tendon Surgery for Postoperative Pain Reduction in Diabetics: A Case Series
4. Brandon Brooks, DPM PGY-3; Bradley Brooks, DO PGY-2; Brady Brooks, MSII; Richa Patel, DPM PGY-2; Anubha Oberoi, DPM PGY-1; Charles Kean, DPM: Concurrent Use of Cyclical Pressure Topical Wound Oxygen Therapy & Umbilical Cord Allograft in a Diabetic with a Pressure Ulceration of the Right Posterior Leg with Exposed Achilles Tendon: A Case Study
5. Jeremy J. Lim, PhD; Jennifer Lei, PhD;  Jenn D. Bullard; Anna M. Fallon, PhD; Michelle Massee; Thomas J. Koob, PhD: Evaluation of Dehydrated Human Umbilical Cord Biological Properties for Wound Care and Soft Tissue Healing

About MiMedx

MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.3 million allografts to date. For additional information, please visit www.mimedx.com.

View original content:http://www.prnewswire.com/news-releases/mimedx-to-present-clinical-and-scientific-studies-at-desert-foot-conference-300744879.html

SOURCE MiMedx Group, Inc.